Clinical Trial · NCT03606837

Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Patients Diagnosed With Intermediate Risk Prostate Cancer Candidates for Radical Prostatectomy

Overview

Patients with primary intermediate risk prostate cancer for whom radical prostatectomy is indicated, will be invited to participate to the present study. Positron Emission Tomography coupled with scanner (PET-CT) using a radiotracer : 68Ga-RM2 and Positron Emission Tomography coupled with scanner (PET-CT) using another radiotracer : 68Ga-PSMA-617, will be scheduled.

Sponsor

University Hospital, Bordeaux

Phase

Phase 2

Contacts

Henri CLERMONT-GALLERANDE (Principal Investigator)

henri.de-clermont-galleran@chu-bordeaux.fr

05 56 79 55 40

Clément MORGAT

clement.morgat@chu-bordeaux.fr

05 56 79 55 40

ClinicalTrials.gov

NCT03606837

Drug / Compound

Isotope(s):
Target(s):